APA (7th ed.) Citation

Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., . . . Kim, K. (2026). Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine, 394(8), 739. https://doi.org/10.1056/NEJMoa2514663

Chicago Style (17th ed.) Citation

Costa, L. J., et al. "Teclistamab Plus Daratumumab in Relapsed or Refractory Multiple Myeloma." New England Journal of Medicine 394, no. 8 (2026): 739. https://doi.org/10.1056/NEJMoa2514663.

MLA (9th ed.) Citation

Costa, L. J., et al. "Teclistamab Plus Daratumumab in Relapsed or Refractory Multiple Myeloma." New England Journal of Medicine, vol. 394, no. 8, 2026, p. 739, https://doi.org/10.1056/NEJMoa2514663.